Furthermore, VEGF-A induces the upregulation of multiple immune checkpoints, such as PD-1, CTLA4, TIM3 and LAG3, in tumor-infiltrating CD8+ T cells, and VEGF-silencing potentiates tumor control mediated by the PD-1 blockade [63]. The gene discussed is HAVCR2; the disease is neoplasm.